TY - JOUR
T1 - Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice
AU - Udayappan, Shanthadevi
AU - Manneras-Holm, Louise
AU - Chaplin-Scott, Alice
AU - Belzer, Clara
AU - Herrema, Hilde
AU - Dallinga-Thie, Geesje M.
AU - Duncan, Silvia H.
AU - Stroes, Erik S. G.
AU - Groen, Albert K.
AU - Flint, Harry J.
AU - Backhed, Fredrik
AU - de Vos, Willem M.
AU - Nieuwdorp, Max
PY - 2016
Y1 - 2016
N2 - An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared with heat-inactivated controls. Our data suggest that E. hallii administration potentially alters the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype
AB - An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared with heat-inactivated controls. Our data suggest that E. hallii administration potentially alters the function of the intestinal microbiome and that microbial metabolites may contribute to the improved metabolic phenotype
U2 - https://doi.org/10.1038/npjbiofilms.2016.9
DO - https://doi.org/10.1038/npjbiofilms.2016.9
M3 - Article
C2 - 28721246
SN - 2055-5008
VL - 2
SP - 16009
JO - NPJ biofilms and microbiomes
JF - NPJ biofilms and microbiomes
ER -